Josh Blacher, CFO at Therapix Biosciences, describes how his company are developing a therapeutic approach to obstructive sleep apnea, and in parallel are developing a synthetic cannabinoid-based tablet to treat Tourette’s Syndrome.
What are cannabinoids?
Cannabinoids (e.g., THC and CBD) are the chemical compounds secreted by cannabis flowers that provide relief to an array of symptoms including pain, nausea, anxiety, and inflammation. These work by imitating compounds our bodies naturally produce, called endocannabinoids, which activate to maintain internal stability and health. To put a complex system simply, they mediate communication between cells, and when there is a deficiency or problem with our endocannabinoid system, unpleasant symptoms and physical complications occur.
Therapix are running a Phase IIa clinical trail for Tourette’s Syndrome Yale at Yale University with data due in a month or so, and also a Phase IIa study for sleep apnea.
According to Therapix, the market potential for sleep apnea in the States is up to 150 billion dollars, and for Tourette’s it is 1.5 billion dollars, and Therapix hope to bring tablet-based therapies to market in 2020 or 2021.
Therapix are NASDAQ-listed: TRPX
This interview is one of a series with Edison pharma clients shot at the Biotech and Money Conference at the Waldorf Hotel, London on 14.11.2017.